This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Arnold, L. E. Search for Related Content PubMed Articles by Arnold, L. E. Social Bookmarking                         What's this?

Methyiphenidate vs. amphetamine: Comparative review

Ohio State University in Columbus, Ohio; 479 S. Galena Rd., Sunbury, OH 43074 (tel. 614-965-1005; fax 614-965-4425; <Arnold.6{at}osu.edu>.

This article compares the two most common medications for Attention-Deficit/Hyperactivity Disorder (ADHD), using data from controlled studies. Medline and Psychinfo searches were done for 1984-1996 with the key words methylphenidate (MPH) and amphetamine (AMP); these were supplemented with known prior and recent literature. Of 92 animal studies found, 15 showed clear differences between the two drugs. Ten reports of controlled crossover ADHD clinical trials (three in the same sample) and a dozen other articles comparing the two drugs in humans were found. MPH is a pure re-uptake inhibitor of catecholamines, especially dopamine; AMP also releases catecholamines. Lab animals showed differential interactions with other drugs and with behavioral paradigms. Human response profiles are noncongruent. An ADHD patient who fails on one stimulant should try the other. Of 174 patients in the 6 clearest crossover studies, 48 responded better to AMP, 27 to MPH, and at least 72 to both, which is an 87+% overall response rate if both are tried. All crossovers, except the one with comorbid Tourette's, showed a nonsignificant tendency for AMP superiority in response rate. Summed data suggest suspected differences in side effects (AMP more sleep and appetite loss and exacerbation of tics in comorbid Tourette's, MPH possibly more depression/apathy and stomachaches) and effects on comorbid disorders (AMP better for conduct/oppositional symptoms, MPH for Tourette's and possibly learning disorder (LD). Most of the clinical differences are tendencies rather than statistically significant.

Journal of Attention Disorders, Vol. 3, No. 4, 200-211 (2000)
DOI: 10.1177/108705470000300403


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				H. M. Conklin, S. Helton, J. Ashford, R. K. Mulhern, W. E. Reddick, R. Brown, M. Bonner, B. W. Jasper, S. Wu, X. Xiong, et al. Predicting Methylphenidate Response in Long-Term Survivors of Childhood Cancer: A Randomized, Double-Blind, Placebo-Controlled, Crossover Trial J. Pediatr. Psychol., May 22, 2009; (2009) jsp044v1. [Abstract] [Full Text] [PDF]

				Practice Parameter for the Assessment and Treatment of Children and Adolescents With Attention-Deficit/Hyperactivity Disorder Focus, July 1, 2008; 6(3): 401 - 426. [Abstract] [Full Text] [PDF]

				B. Vitiello Improving Decision Making in the Treatment of ADHD Am J Psychiatry, June 1, 2008; 165(6): 666 - 667. [Full Text] [PDF]

				B. P. Daly and R. T. Brown Scholarly Literature Review: Management of Neurocognitive Late Effects with Stimulant Medication J. Pediatr. Psychol., October 1, 2007; 32(9): 1111 - 1126. [Abstract] [Full Text] [PDF]

				L. L. Greenhill, S. Pliszka, M. K. Dulcan, W. Bernet, V. Arnold, J. Beitchman, R. S. Benson, O. Bukstein, J. Kinlan, J. McClellan, et al. Practice Parameter for the Use of Stimulant Medications in the Treatment of Children, Adolescents, and Adults Focus, October 1, 2004; 2(4): 642 - 668. [Abstract] [Full Text] [PDF]

				S. Grcevich Review: adderall may have a small advantage over methylphenidate in attention deficit hyperactivity disorder Evid. Based Ment. Health, May 1, 2003; 6(2): 43 - 43. [Full Text] [PDF]